<DOC>
	<DOCNO>NCT01506154</DOCNO>
	<brief_summary>A Randomized , Multi-Center , Double-Blind , Placebo-Controlled Phase III Trial Evaluate Efficacy , Tolerability Safety MRX-7EAT Etodolac-Lidocaine Topical Patch Treatment Pain due Recent Onset Supraspinatous and/or Subacromial Tendonitis/Bursitis and/or Subdeltoid Bursitis Shoulder .</brief_summary>
	<brief_title>Safety &amp; Efficacy Study MRX-7EAT Patch Treatment Pain Shoulder</brief_title>
	<detailed_description />
	<mesh_term>Shoulder Pain</mesh_term>
	<mesh_term>Tendinopathy</mesh_term>
	<mesh_term>Bursitis</mesh_term>
	<criteria>Females child bear potential must negative pregnancy test use adequate method birth control . Subject diagnosis acute supraspinatous subacromial bursitis/tendonitis and/or subdeltoid bursitis one shoulder onset current episode ≥ 24 hour ≤ 7 day precede screen visit . Subject Current Pain Intensity rat prior study entry ≥ 6 ≤ 8 Numeric Pain Rating Scale ( NPRS ) . Subject suspect tear rotator cuff , calcific tendonitis , adhesive capsulitis , shoulder fracture , bilateral shoulder pain , bilateral tendonitis and/or bursitis shoulder , bicipital tendonitis ; orthopedic surgical treatment require . Subject positive Drop Arm Test indicative suspect tear ; positive O'Brien 's Test suggestive glenoid labral tear ; positive Apprehension Test would indicative glenohumeral instability ; positive Yergason 's Test would indicative bicipital tendonitis . Subject previous episode shoulder pain area within two week prior current episode ; history chronic pain target shoulder ; history rotator cuff injury previous surgery area . Subject receive passive physical therapy treatment pain target shoulder within past 24 hour . Subject use oral pharmacologic treatment le 5 halflives baseline assessment . Subject use form opioid within 24 hour study entry use opioids 5 consecutive day within 30 day precede enrollment . Subject receive systemic corticosteroid 30 day precede screening visit ; local injection intraarticular , bursal , peritendinous ; topical corticosteroid acceptable unless applied target joint ; inhale intranasal steroid acceptable ( e.g. , Flonase® ) . Subject recently initiate sleep medication , muscle relaxant , anticonvulsant antidepressant ( within past 30 day ) . Subject use TNF alpha blocker Class 1 antiarrhythmic drug within past 60 day . Subject history physical assessment find clinically significant GI ulcer abnormal bleeding , anemia , kidney disease , liver disease , poorly control lung , stomach , heart , vital organ disease determine study investigator/physician . Subject fibromyalgia , spondyloarthropathies ( SpA ) systemic arthritis rheumatoid arthritis . Arthritis typically localize gout osteoarthritis acceptable long affect injure area . Subject painful syndrome ( e.g . sciatica ) cervical spine disorder lead nerve entrapment syndrome medical problem investigator 's opinion may interfere pain measurement target joint . Subject active skin lesion disease intend site study medication application , may cover patch . Skin lesion include open wound , rash , papules vesicle ; abrasion , laceration break skin . Subject history allergy etodolac , NSAIDs , lidocaine adhesive ( e.g. , adhesive tape ) . Subject schedule elective surgery invasive procedure period study participation .</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>bursitis/tendonitis and/or subdeltoid bursitis</keyword>
</DOC>